Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines.
Frederic DebellutKevin TangAndrew ClarkClint PecenkaBachir AssaoOusmane GuindoRebecca F GraisSheila IsanakaPublished in: BMJ open (2022)
This study can inform decision-making around rotavirus vaccination policy in Niger, demonstrating that ROTAVAC is likely the most cost-effective option. Alternative products (ROTASIIL and ROTARIX) may also be considered by decision-makers if they are priced more competitively, or if their cold chain requirements could bring additional economic benefits.